Citations (91)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Roberto Castelli, Nicola Orofino, Agnese Losurdo, Roberta Gualtierotti & Massimo Cugno. (2014) Choosing treatment options for patients with relapsed/refractory multiple myeloma. Expert Review of Anticancer Therapy 14:2, pages 199-215.
Read now
Read now
Swati Andhavarapu & Vivek Roy. (2013) Immunomodulatory drugs in multiple myeloma. Expert Review of Hematology 6:1, pages 69-82.
Read now
Read now
Roberto Castelli, Antonino Cannavò, Fabio Conforti, Giovanni Grava & Agostino Cortelezzi. (2012) Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice. Immunopharmacology and Immunotoxicology 34:5, pages 740-753.
Read now
Read now
Javier de la Rubia & Mónica Roig. (2011) Bortezomib for previously untreated multiple myeloma. Expert Review of Hematology 4:4, pages 381-398.
Read now
Read now
Ajai Chari, Amitabha Mazumder & Sundar Jagannath. (2010) Proteasome inhibition and its therapeutic potential in multiple myeloma. Biologics: Targets and Therapy 4, pages 273-287.
Read now
Read now
M. Wang, K. Delasalle, S. Giralt & R. Alexanian. (2010) Rapid control of previously untreated multiple myeloma with bortezomib–lenalidomide–dexamethasone (BLD). Hematology 15:2, pages 70-73.
Read now
Read now
Paul G Richardson, Constantine Mitsiades, Robert Schlossman, Irene Ghobrial, Teru Hideshima, Nikhil Munshi & Kenneth C Anderson. (2008) Bortezomib in the front-line treatment of multiple myeloma. Expert Review of Anticancer Therapy 8:7, pages 1053-1072.
Read now
Read now
Muralikrishnan Srikanth, Faith E Davies & Gareth J Morgan. (2008) An update on drug combinations for treatment of myeloma. Expert Opinion on Investigational Drugs 17:1, pages 1-12.
Read now
Read now
Articles from other publishers (83)
Ahmed Ismail Eatmann, Esraa Hamouda, Heba Hamouda, Hossam Khaled Farouk, Afnan W. M. Jobran, Abdallah A. Omar, Alyaa Khaled Madeeh, Nada Mostafa Al-dardery, Salma Elnoamany, Eman Gamal Abd-Elnasser, Abdullah Muhammed Koraiem, Alhassan Ali Ahmed, Mohamed Abouzid & Marta Karaźniewicz-Łada. (2023) Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview. Metabolites 13:4, pages 543.
Crossref
Crossref
Sameh Nassar, Gregory P. Kaufman, Ahmed Taher, John E. Madewell & Bilal Mujtaba. 2023. Oncologic Imaging : a Multidisciplinary Approach. Oncologic Imaging : a Multidisciplinary Approach
503
528
.
Sarah Farag, Ulrike Bacher, Barbara Jeker, Myriam Legros, Gaelle Rhyner, Jean-Marc Lüthi, Julian Schardt, Thilo Zander, Michael Daskalakis, Behrouz Mansouri, Chantal Manz & Thomas Pabst. (2022) Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial. Bone Marrow Transplantation 57:6, pages 990-997.
Crossref
Crossref
Laurent Garderet, Giulia Sbianchi, Simona Iacobelli, Didier Blaise, Jenny L. Byrne, Peter Remenyi, Jane F. Apperley, Cyrille Touzeau, Cecilia Isaksson, Paul Browne, Jiri Mayer, Stig Lenhoff, Soledad Gonzalez Muniz, Rocio Parody Porras, Grzegorz Basak, Xavier Poire, Marek Trneny, Arnon Nagler, Mariagrazia Michieli, Alina Tanase, Linda Koster, Patrick J. Hayden, Meral Beksac, Stefan Schönland & Ibrahim Yakoub‐Agha. (2021) Prognostic impact of early‐versus‐late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT. European Journal of Haematology 106:5, pages 708-715.
Crossref
Crossref
Guillermo J. Ruiz-Argüelles & David Gómez-Almaguer. (2021) Lessons Learned Treating Patients with Multiple Myeloma in Resource-Constrained Settings. Current Hematologic Malignancy Reports 16:1, pages 40-44.
Crossref
Crossref
Côme Bommier, Alexis Talbot, Stéphanie Harel, Wendy Cuccuini, Laurence Gérard & Bertrand Arnulf. (2020) Exploratory analysis of intensified conditioning as first line treatment for patients with high risk multiple myeloma. Hematological Oncology 38:4, pages 517-522.
Crossref
Crossref
Roberto Ria, Assunta Melaccio, Vito Racanelli & Angelo Vacca. (2020) Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients. Journal of Clinical Medicine 9:6, pages 1765.
Crossref
Crossref
Ioannis Ntanasis-Stathopoulos, Evangelos Terpos & Meletios A. Dimopoulos. (2019) Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma. The Cancer Journal 25:1, pages 2-10.
Crossref
Crossref
Min Chen, Yongfeng Zhao, Chuanxin Xu, Xian Wang, Xianping Zhang & Benyu Mao. (2018) Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. Annals of Hematology 97:6, pages 925-944.
Crossref
Crossref
D Sivaraj, W Bacon, G D Long, D A Rizzieri, M E Horwitz, K M Sullivan, Y Kang, Z Li, N J Chao & C Gasparetto. (2017) High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transplantation 53:1, pages 34-38.
Crossref
Crossref
Shaji K. Kumar, Jacob P. Laubach, Thomas J. Giove, Maureen Quick, Rachel Neuwirth, Godwin Yung, S. Vincent Rajkumar & Paul G. Richardson. (2017) Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. British Journal of Haematology 178:5, pages 756-763.
Crossref
Crossref
Sarah A. Holstein & Philip L. McCarthy. (2017) Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. Drugs 77:5, pages 505-520.
Crossref
Crossref
Merav Leiba, Meirav Kedmi, Adrian Duek, Tzachi Freidman, Mia Weiss, Ronit Leiba, Arnon Nagler & Abraham Avigdor. (2014)
Bortezomib-Cyclophosphamide-Dexamethasone (VCD)
versus
Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis
. British Journal of Haematology 166:5, pages 702-710.
Crossref
Crossref
Hejing Huang, Lili Zhou, Lihui Peng, Weijun Fu, Chunyang Zhang & Jian Hou. (2014) Bortezomib–thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: A meta-analysis of phase III randomized controlled trials. Leukemia Research 38:9, pages 1048-1054.
Crossref
Crossref
R Alexanian, M Wang, K Delasalle, S Wang, M Qazilbash, B Handy & D Weber. (2013) Value of novel agents and intensive therapy for patients with multiple myeloma. Bone Marrow Transplantation 49:3, pages 422-425.
Crossref
Crossref
Shaji Kumar & Steven J. Russell. 2014. Multiple Myeloma. Multiple Myeloma
81
94
.
Philippe Moreau & Cyrille Touzeau. (2013) Initial Treatment of Transplant Candidates With Multiple Myeloma. Seminars in Oncology 40:5, pages 585-591.
Crossref
Crossref
P Moreau & C Touzeau. (2013) Optimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation. Leukemia Supplements 2:S1, pages S15-S20.
Crossref
Crossref
Alessandra Romano, Concetta Conticello & Francesco Di Raimondo. (2013) Bortezomib for the treatment of previously untreated multiple myeloma. Immunotherapy 5:4, pages 327-352.
Crossref
Crossref
Raymond Alexanian, Kay Delasalle & Michael Wang. (2013) High Frequencies of Response After Limited Primary Therapy for Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 13:2, pages 119-122.
Crossref
Crossref
P. Casassus. (2013) Traitement du myélome multiple. EMC - Hématologie 8:1, pages 1-16.
Crossref
Crossref
Utkarsh PainulyShaji Kumar. (2013) Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma. Clinical Medicine Insights: Oncology 7, pages CMO.S7764.
Crossref
Crossref
Gabriele Buda, Enrico Orciuolo, Giovanni Carulli, Sara Galimberti, Francesco Ghio, Giulia Cervetti, Matteo Pelosini & Mario Petrini. (2013) Bortezomib with Thalidomide plus Dexamethasone Compared with Thalidomide plus Doxorubicin and Dexamethasone as Induction Therapy in Previously Untreated Multiple Myeloma Patients. Acta Haematologica 129:1, pages 35-39.
Crossref
Crossref
Weijun Fu, Kay Delasalle, Jialei Wang, Shen Song, Jian Hou, Raymond Alexanian & Michael Wang. (2012) Bortezomib-Cyclophosphamide-Dexamethasone for Relapsing Multiple Myeloma. American Journal of Clinical Oncology 35:6, pages 562-565.
Crossref
Crossref
Laura RosiñolAlbert OriolAna Isabel TeruelDolores HernándezJavier López-JiménezJavier de la RubiaMiquel GranellJoan BesalduchLuis PalomeraYolanda GonzálezMª Asunción EtxebesteJoaquín Díaz-MediavillaMiguel T. HernándezFelipe de ArribaNorma C. GutiérrezMª Luisa Martín-Ramos, Mª Teresa CibeiraMª Victoria MateosJoaquín Martínez, Adrián Alegre, Juan José Lahuerta, Jesús San MiguelJoan Bladé. (2012) Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 120:8, pages 1589-1596.
Crossref
Crossref
Philippe MoreauPaul G. RichardsonMichele CavoRobert Z. OrlowskiJesús F. San MiguelAntonio Palumbo & Jean-Luc Harousseau. (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120:5, pages 947-959.
Crossref
Crossref
Raymond Alexanian, Kay Delasalle, Michael Wang, Sheeba Thomas & Donna Weber. (2012) Curability of Multiple Myeloma. Bone Marrow Research 2012, pages 1-5.
Crossref
Crossref
Tamara Miner Haygood, Edith M. Marom & Donna M. Weber. 2012. Oncologic Imaging: A Multidisciplinary Approach. Oncologic Imaging: A Multidisciplinary Approach
509
529
.
Boris Cvek. 2012. The Proteasomal System in Aging and Disease. The Proteasomal System in Aging and Disease
161
226
.
Shayne Cox GadBalveen Kaur, Gregory B. Lesinski & Abhik Ray Chaudhary. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia.
P. Moreau, H. Avet-Loiseau, T. Facon, M. Attal, M. Tiab, C. Hulin, C. Doyen, L. Garderet, E. Randriamalala, C. Araujo, G. Lepeu, G. Marit, D. Caillot, M. Escoffre, B. Lioure, L. Benboubker, B. Pegourie, B. Kolb, A. M. Stoppa, J.-G. Fuzibet, O. Decaux, M. Dib, C. Berthou, C. Chaleteix, C. Sebban, C. Traulle, J. Fontan, M. Wetterwald, P. Lenain, C. Mathiot & J.-L. Harousseau. (2011) Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118:22, pages 5752-5758.
Crossref
Crossref
Andrzej J. JakubowiakKent A. GriffithDonna E. ReeceCraig C. HofmeisterSagar LonialTodd M. ZimmermanErica L. CampagnaroRobert L. SchlossmanJacob P. LaubachNoopur S. RajeTara AndersonMelissa A. MietzelColleen K. HarveySandra M. WearJennifer C. BarrickmanCraig L. Tendler, Dixie-Lee Esseltine, Susan L. KelleyMark S. KaminskiKenneth C. AndersonPaul G. Richardson. (2011) Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood 118:3, pages 535-543.
Crossref
Crossref
Michele CavoS. Vincent RajkumarAntonio PalumboPhilippe MoreauRobert OrlowskiJoan BladéOrhan SezerHeinz LudwigMeletios A. DimopoulosMichel AttalPieter SonneveldMario BoccadoroKenneth C. AndersonPaul G. RichardsonWilliam BensingerHans E. JohnsenNicolaus KroegerGösta GahrtonP. Leif BergsagelDavid H. VesoleHermann EinseleSundar JagannathRuben NiesvizkyBrian G. M. DurieJesus San Miguel & Sagar Lonial. (2011) International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 117:23, pages 6063-6073.
Crossref
Crossref
Philippe MoreauHervé Avet-LoiseauJean-Luc HarousseauMichel Attal. (2011) Current Trends in Autologous Stem-Cell Transplantation for Myeloma in the Era of Novel Therapies. Journal of Clinical Oncology 29:14, pages 1898-1906.
Crossref
Crossref
Michihide Tokuhira, Reiko Watanabe, Tomoe Nemoto, Kyoko Hanzawa, Morihiko Sagawa, Takeshi Tomikawa, Shigehisa Mori & Masahiro Kizaki. (2011) Successful treatment with a modified bortezomib schedule of weekly and longer intervals for patients with refractory/resistance multiple myeloma. Leukemia Research 35:5, pages 591-597.
Crossref
Crossref
M. CARRIER, G. LE GAL, J. TAY, C. WU & A.Y. LEE. (2011) Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta‐analysis. Journal of Thrombosis and Haemostasis 9:4, pages 653-663.
Crossref
Crossref
Nilanjan Ghosh, Xiaobu Ye, Anna Ferguson, Carol Ann Huff & Ivan Borrello. (2011) Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma. British Journal of Haematology 152:5, pages 593-599.
Crossref
Crossref
A Nitta-Seko, N Nitta, A Sonoda, H Otani, K Tsuchiya, S Ohta, M Takahashi & K Murata. (2011) Anti-tumour effects of transcatheter arterial embolisation administered in combination with thalidomide in a rabbit VX2 liver tumour model. The British Journal of Radiology 84:998, pages 179-183.
Crossref
Crossref
Yunfeng Shen, Xin Zhou, Zhi Wang, Guohua Yang, Yuanqiang Jiang, Chao Sun, Jing Wang, Yi Tong & Hongfeng Guo. (2011) Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma. Leukemia Research 35:2, pages 147-151.
Crossref
Crossref
Jesús F. San Miguel & María -Victoria Mateos. 2011. Bortezomib in the Treatment of Multiple Myeloma. Bortezomib in the Treatment of Multiple Myeloma
53
68
.
Michele Cavo, Paola Tacchetti, Francesca Patriarca, Maria Teresa Petrucci, Lucia Pantani, Monica Galli, Francesco Di Raimondo, Claudia Crippa, Elena Zamagni, Antonio Palumbo, Massimo Offidani, Paolo Corradini, Franco Narni, Antonio Spadano, Norbert Pescosta, Giorgio Lambertenghi Deliliers, Antonio Ledda, Claudia Cellini, Tommaso Caravita, Patrizia Tosi & Michele Baccarani. (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. The Lancet 376:9758, pages 2075-2085.
Crossref
Crossref
Massimo Offidani, Pietro Leoni, Laura Corvatta, Claudia Polloni, Silvia Gentili, Anna Marina Liberati, Stefano Pulini, Alessandro Gozzetti, Stelvio Ballanti, Chiara Nozzoli & Antonio Palumbo. (2010) Outcome and Toxicity in the Modern Era of New Drugs for Multiple Myeloma: A Reappraisal for Comparison With Future Investigational Trials. Clinical Lymphoma Myeloma and Leukemia 10:5, pages 353-360.
Crossref
Crossref
Shi-Lun Chen, Bin Jiang, Lu-Gui Qiu, Li Yu, Yu-Ping Zhong & Wen Gao. (2010) Bortezomib Plus Thalidomide for Newly Diagnosed Multiple Myeloma in China. The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology 293:10, pages 1679-1684.
Crossref
Crossref
A. Keith Stewart. (2010) Union of forces advances myeloma care. Blood 116:5, pages 674-675.
Crossref
Crossref
Jonathan L. Kaufman, Ajay Nooka, Mark Vrana, Charise Gleason, L. Thompson Heffner & Sagar Lonial. (2010) Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma. Cancer 116:13, pages 3143-3151.
Crossref
Crossref
Hongfeng Guo, Xin Zhou, Yuanqiang Jiang, Guohua Yang, Chao Sun, Yun Zhuang, Hongli Sun, Mize Lu, Xifeng Qian, Feng Chen, Jingjue Mao, Heng Chen, Jun Xia & Yunfeng Shen. (2010) Bortezomib plus intermediate‐dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: A Chinese experience. American Journal of Hematology 85:7, pages 499-501.
Crossref
Crossref
Shayne Cox GadBalveen Kaur, Gregory B. Lesinski & Abhik Ray Chaudhury. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia.
Joan Bladé, Laura Rosiñol, Maria Teresa Cibeira, Montserrat Rovira & Enric Carreras. (2010) Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 115:18, pages 3655-3663.
Crossref
Crossref
David Dingli & S. Vincent Rajkumar. (2010) How best to use new therapies in multiple myeloma. Blood Reviews 24:3, pages 91-100.
Crossref
Crossref
Craig B. Reeder, Donna E. Reece, Vishal Kukreti, Christine Chen, Suzanne Trudel, Kristina Laumann, Joseph Hentz, Nicholas A. Pirooz, Jesus G. Piza, Rodger Tiedemann, Joseph R. Mikhael, Peter L. Bergsagel, Jose F. Leis, Rafael Fonseca & Alexander K. Stewart. (2010) Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 115:16, pages 3416-3417.
Crossref
Crossref
Klaus PodarKenneth C. Anderson. (2010) Targeting the Ubiquitin-proteasome System for the Treatment of Multiple Myeloma and Other Human Diseases. Clinical Medicine Insights: Therapeutics 2, pages CMT.S2889.
Crossref
Crossref
David H. Vesole. 2010. Allogeneic Stem Cell Transplantation. Allogeneic Stem Cell Transplantation
143
157
.
A. Keith StewartPaul G. Richardson & Jesus F. San-Miguel. (2009) How I treat multiple myeloma in younger patients. Blood 114:27, pages 5436-5443.
Crossref
Crossref
Shaji K. Kumar, Joseph R. Mikhael, Francis K. Buadi, David Dingli, Angela Dispenzieri, Rafael Fonseca, Morie A. Gertz, Philip R. Greipp, Suzanne R. Hayman, Robert A. Kyle, Martha Q. Lacy, John A. Lust, Craig B. Reeder, Vivek Roy, Stephen J. Russell, Kristen E. Detweiler Short, A. Keith Stewart, Thomas E. Witzig, Steven R. Zeldenrust, Robert J. Dalton, S. Vincent Rajkumar & P. Leif Bergsagel. (2009) Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. Mayo Clinic Proceedings 84:12, pages 1095-1110.
Crossref
Crossref
Weiyan Zheng, Guoqing Wei, Xiujin Ye, Jingsong He, Li Li, Wenjun Wu, Jimin Shi, Jie Zhang, Weijia Huang, Wanzhuo Xie, Yi Luo, Xingkui Xue, Maofang Lin, He Huang & Zhen Cai. (2009) Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience. Leukemia Research 33:12, pages 1615-1618.
Crossref
Crossref
J J Shah & R Z Orlowski. (2009) Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23:11, pages 1964-1979.
Crossref
Crossref
Andrzej J. JakubowiakTara KendallAmmar Al-ZoubiYasser KhaledShin MineishiAsra AhmedErica CampagnaroChristine BrozoThomas BraunMoshe TalpazMark S. Kaminski. (2009) Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma. Journal of Clinical Oncology 27:30, pages 5015-5022.
Crossref
Crossref
C B Reeder, D E Reece, V Kukreti, C Chen, S Trudel, J Hentz, B Noble, N A Pirooz, J E Spong, J G Piza, V H J Zepeda, J R Mikhael, J F Leis, P L Bergsagel, R Fonseca & A K Stewart. (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 23:7, pages 1337-1341.
Crossref
Crossref
Sagar Lonial & Jamie Cavenagh. (2009) Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. British Journal of Haematology 145:6, pages 681-708.
Crossref
Crossref
Tomoya Fukui, Yasuo Kodera, Kazuto Nishio, Noriyuki Masuda, Tomohide Tamura & Fumiaki Koizumi. (2009) Synergistic interactions between the synthetic retinoid tamibarotene and glucocorticoids in human myeloma cells. Cancer Science 100:6, pages 1137-1143.
Crossref
Crossref
G L Uy, S D Goyal, N M Fisher, A Y Oza, M H Tomasson, K Stockerl-Goldstein, J F DiPersio & R Vij. (2008) Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study. Bone Marrow Transplantation 43:10, pages 793-800.
Crossref
Crossref
Todd Zimmerman. (2009) Immunomodulatory agents in oncology. Update on Cancer Therapeutics 3:4, pages 170-181.
Crossref
Crossref
Mark A. Dawson, Stephen S. Opat, Yamna Taouk, Mark Donovan, Michele Zammit, Katherine Monaghan, Noemi Horvath, Andrew W. Roberts, H. Miles Prince, Mark Hertzberg, Catriona A. McLean & Andrew Spencer. (2009) Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma. Clinical Cancer Research 15:2, pages 714-722.
Crossref
Crossref
Tomer Mark, Ruben Niesvizky & Morton Coleman. (2009) Novel agents in myeloma: An exciting saga. Cancer 115:2, pages 236-242.
Crossref
Crossref
Shuqing Lü, Jianmin Wang, Xiaoqian Xu, Xiong Ni, Chongmei Huang, Huiying Qiu, Xiaoxia Hu & Jianmin Yang. (2008) Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience. International Journal of Hematology 89:1, pages 34-38.
Crossref
Crossref
Maurizio Zangari, F. Elice, G. Tricot & L. Fink. 2009. Coagulation in Cancer. Coagulation in Cancer
295
304
.
Joan Bladé & Laura Rosiñol. (2008) Advances in therapy of multiple myeloma. Current Opinion in Oncology 20:6, pages 697-704.
Crossref
Crossref
J.-L. Harousseau. 2009. Treatment of Multiple Myeloma and Related Disorders. Treatment of Multiple Myeloma and Related Disorders
86
100
.
Rafael Fonseca & S. Vincent Rajkumar. (2008) Consolidation Therapy with Bortezomib/Lenalidomide/Dexamethasone Versus Bortezomib/Dexamethasone After a Dexamethasone-Based Induction Regimen in Patients with Multiple Myeloma: A Randomized Phase III Trial. Clinical Lymphoma and Myeloma 8:5, pages 315-317.
Crossref
Crossref
Sagar Lonial, Paul G Richardson, Jesús San Miguel, Pieter Sonneveld, Michael W Schuster, Joan Bladé, Jamie Cavenagh, S. Vincent Rajkumar, Andrzej J Jakubowiak, Dixie-Lee Esseltine, Kenneth C Anderson & Jean-Luc Harousseau. (2008) Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. British Journal of Haematology 143:2, pages 222-229.
Crossref
Crossref
D. Lacruz Guzmán, C. Funes Vera, M. Martínez Penella, M.J. Morales Lara, V. Jorge Vidal & M.C. Mira Sirvent. (2008) Bortezomib como alternativa en el tratamiento de pacientes con gammapatías malignas. Farmacia Hospitalaria 32:5, pages 280-285.
Crossref
Crossref
Jesús San-Miguel, Jean-Luc Harousseau, Douglas Joshua & Kenneth C. Anderson. (2008) Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents. Journal of Clinical Oncology 26:16, pages 2761-2766.
Crossref
Crossref
Stefania Ciolli, Franco Leoni, Cinzia Casini, Carla Breschi, Valeria Santini & Alberto Bosi. (2008) The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. British Journal of Haematology 141:6, pages 814-819.
Crossref
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:2, pages 115-122.
Crossref
Crossref
Qaiser Bashir, Choon-Kee Lee, Rodney W. Stuart, Maxwell L. Smith, John Ryder & Ricardo Gonzalez. (2008) Phenotypic Evolution of Waldenstrom's Macroglobulinemia to Extramedullary Plasmacytoma. Journal of Clinical Oncology 26:14, pages 2408-2410.
Crossref
Crossref
Robert Z. Orlowski & Deborah J. Kuhn. (2008) Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade. Clinical Cancer Research 14:6, pages 1649-1657.
Crossref
Crossref
G. J. MORGAN, F. E. DAVIES, J. D. CAVENAGH & G. H. JACKSON. (2008) Position statement on the use of bortezomib in multiple myeloma. International Journal of Laboratory Hematology 30:1, pages 1-10.
Crossref
Crossref
William Bensinger. (2008) Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs. Journal of Clinical Oncology 26:3, pages 480-492.
Crossref
Crossref
Jean-Luc Harousseau. (2008) Induction Therapy in Multiple Myeloma. Hematology 2008:1, pages 306-312.
Crossref
Crossref
D. Lacruz Guzmán, C. Funes Vera, M. Martínez Penella, M.J. Morales Lara, V. Jorge Vidal & M.C. Mira Sirvent. (2008) Bortezomib as an Alternative in the Treatment of Patients With Malignant Gammopathy. Farmacia Hospitalaria (English Edition) 32:5, pages 280-285.
Crossref
Crossref
M.V. Mateos & J.F. San Miguel. (2007) Bortezomib in multiple myeloma. Best Practice & Research Clinical Haematology 20:4, pages 701-715.
Crossref
Crossref
Patrick J Hayden, Constantine S Mitsiades, Kenneth C Anderson & Paul G Richardson. (2007) Novel therapies in myeloma. Current Opinion in Hematology 14:6, pages 609-615.
Crossref
Crossref
Rami Manochakian, Kena C. Miller & Asher A. Chanan-Khan. (2007) Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma. The Oncologist 12:8, pages 978-990.
Crossref
Crossref